Home > Dermatology > EADV 2022 > Baricitinib: a possible treatment option for children with AD?

Baricitinib: a possible treatment option for children with AD?

Presented By
Dr Antonio Torrelo, Hospital Infantil Universitario Niño Jesús, Spain
EADV 2022
Children that were treated with various dosages of baricitinib for atopic dermatitis (AD) showed significant amelioration in the high dose study arm, according to the BREEZE-AD-PEDS study. A rate of 41.7% achieved a validated Investigator’s Global Assessment (vIGA) of clear or almost clear score. In the phase 3 BREEZE-AD-PEDS trial (NCT03952559), 483 patients aged 2 to <18 years were randomised to 4 study arms, receiving baricitinib either at a low, medium, or high dose, or placebo [1]. Dose regimens were adjusted to <10 years or 10 to <18 years, with daily 0.5 mg/1 mg, 1 mg/2 mg, or 2 mg/4 mg baricitinib. A vIGA of clear or almost clear (0/1) score with at least 2-point improvement from baseline, marked the primary endpoint at week 16. To be included, the patient needed to have moderate-to-severe AD with a history of inadequate response or intolerance of...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on